文献速递免疫规划慢病防控与筛查

自身免疫风湿病患者接种重组带状疱疹疫苗的前瞻性对照研究:静脉环磷酰胺治疗下仍稳健血清转换

Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide.
PubMed 文献 · Vaccine · 2026-10-07

该研究为前瞻性随机安慰剂对照试验的子分析,纳入41例接受静脉环磷酰胺(IVCYC)的自身免疫风湿病(ARD)患者、164例未接受IVCYC的ARD患者和164名健康对照,接种两剂重组带状疱疹疫苗(RZV)。结果显示ARD-IVCYC组与ARD-no IVCYC组血清转换率无差异(91.9% vs. 91.5%),均低于健康对照(99.4%,p=0.022);两组GMTs相当但低于对照(p=0.006),细胞反应和疾病 flare 无组间差异,无严重不良事件。

要点

  • IVCYC治疗的ARD患者接种RZV后血清转换率>90%,与未用IVCYC者相当。
  • ARD患者体液应答低于健康对照,但细胞应答和疾病活动无显著差异。
  • RZV在IVCYC治疗期间未增加严重不良事件,支持有指征时接种。

核心结论

  • RZV在IVCYC治疗的ARD患者中诱导>90%的体液应答,支持有指征时在IVCYC治疗期间接种。

研究设计与样本

  • 前瞻性随机安慰剂对照试验的子分析,纳入41例ARD-IVCYC患者、164例ARD-no IVCYC患者和164名健康对照,接种两剂RZV。

主要发现

  • ARD-IVCYC与ARD-no IVCYC的血清转换率分别为91.9%和91.5%,无差异;健康对照为99.4%(p=0.022)。
  • 接种后GMTs在ARD两组间相当(p>0.999),但低于健康对照(p=0.006)。
  • 细胞反应和ARD flare在各组间无差异(p>0.05),未报告严重不良事件。

临床怎么用

  • 对于接受IVCYC治疗的ARD患者,若有接种指征,可考虑接种RZV,无需因IVCYC而推迟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recombinant zoster vaccine (RZV) prevents shingles in autoimmune rheumatic diseases (ARD), but intravenous cyclophosphamide (IVCYC) impact on immunogenicity is unknown. Given cell depletion/cytotoxicity, IVCYC is expected to induce profound immunogenicity impairment, we therefore evaluated its impact. METHODS: This subanalysis of prospective, randomized, placebo-controlled trial included ARD patients receiving IVCYC (ARD-IVCYC) compared with patients without IVCYC (ARD-no IVCYC) and healthy-controls. RZV was administered in two doses. Humoral response (≥4-fold), geometric mean titers (GMT) and cellular response were assessed after second dose. Disease activity and adverse events (AEs) were recorded. RESULTS: Forty-one ARD-IVCYC, 164 ARD-no IVCYC, and 164 controls were included. Seroconversion did not differ between ARD-IVCYC and ARD-no IVCYC (91.9% vs. 91.5%) and were lower than controls (99.4%, p = 0.022). Post-vaccination GMTs were comparable between ARD groups (p > 0.999), but lower than controls (p = 0.006). Cellular response and ARDs flares did not differ between groups (p > 0.05), with no severe AEs. CONCLUSION: RZV elicited >90% humoral response in IVCYC-treated patients, supporting it during IVCYC when warranted (NCT05879419).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Aikawa NE, Medeiros JB, Pasoto SG, et al. Prospective controlled study of the recombinant zoster vaccine in autoimmune rheumatic disease: robust seroconversion despite intravenous cyclophosphamide. Vaccine. 2026. PMID: 42843284. doi:10.1016/j.vaccine.2026.129227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。